Pharmaceuticals France

France Cancer Immunotherapy Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

France Cancer Immunotherapy Market Industry Trends and Forecast to 2034: Segmented by (Type, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

France · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $3.30 Bn Placeholder estimate
Estimate 2025 $3.64 Bn 2.7% of the global market
Projected 2034 $8.65 Bn 137.7% Adds $5.01 Bn over 9 forecast years
CAGR 2025–2034 10.1% Faster than 64% of 180 Pharmaceuticals markets here
Key players 5
  • France is 2.68% of the global market.
  • In Europe, the largest is Germany at $4.14 Bn.
  • Fastest growing: Russia at 10.9% a year.
  • France ranks 2nd of 6 by size in Europe.

Market size projection

France

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$5.01 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Cancer Immunotherapy Market market size by year, France
YearMarket sizeChange that yearSince 2025
2024 (estimate) $3.30 Bn — —
2025 (base) $3.64 Bn +$333.7 Mn —
2026 (forecast) $4.00 Bn +$367.4 Mn +10.1%
2027 (forecast) $4.41 Bn +$404.5 Mn +21.2%
2028 (forecast) $4.85 Bn +$445.3 Mn +33.5%
2029 (forecast) $5.34 Bn +$490.3 Mn +46.9%
2030 (forecast) $5.88 Bn +$539.8 Mn +61.8%
2031 (forecast) $6.48 Bn +$594.3 Mn +78.1%
2032 (forecast) $7.13 Bn +$654.4 Mn +96.1%
2033 (forecast) $7.85 Bn +$720.4 Mn +115.9%
2034 (forecast) $8.65 Bn +$793.2 Mn +137.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

France Cancer Immunotherapy Market Analysis at a glance
Market size, 2025$3.64 Bn placeholder estimate
Forecast, 2034$8.65 Bn placeholder estimate
Growth (CAGR), 2025–203410.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, indication and end user (see all)
Key playersMerck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Regeneron Pharmaceuticals (see all)
Regulator in FranceANSMSource: ANSM, French medicines agency. Checked 14 Nov 2026.
Active clinical trials184 in FranceSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The France Cancer Immunotherapy Market Analysis Executive Summary

Cancer immunotherapy helps the immune system fight cancer, using checkpoint inhibitors, cell therapies, vaccines and other immune drugs.

Key segments of the cancer Immunotherapy market include type (Checkpoint Inhibitors, Cell Therapies and Cancer Vaccines) and indication (Lung Cancer, Melanoma and Blood Cancers).

Bar chart: France Cancer Immunotherapy market size, 2024–2034, placeholder estimates. $3.30 Bn in 2024, $3.64 Bn in 2025 and $8.65 Bn in 2034, 10.1% CAGR.
France Cancer Immunotherapy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

France Cancer Immunotherapy Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the cancer Immunotherapy market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the cancer Immunotherapy market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the cancer Immunotherapy market, especially in low- and middle-income countries.

Competitive Landscape for Cancer Immunotherapy Market in France

The cancer Immunotherapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Cancer Immunotherapy Market in France

Cancer Immunotherapy in France: rules, payment and research

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency.⁠[1] National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover.⁠[2] ClinicalTrials.gov lists 184 studies on Cancer Immunotherapy that are recruiting, active or about to start in France.⁠[3]

[1] ANSM, French medicines agency. Checked 14 Nov 2026.

[2] Assurance Maladie (ameli.fr). Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for cancer Immunotherapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in France.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Cancer Immunotherapy right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Cancer Immunotherapy in context

France compared

  • Health spending per person: 5,327 US$ per person (2024). World: 1,317 US$ per person (2023). 3rd highest of the 6 countries we cover in Europe.[1]
  • Doctors: 3.28 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 6th highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 22.5% of people (2025). World: 10.4% of people (2025). 3rd highest of the 6 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Cancer Immunotherapy market in France?
Placeholder estimate: about $3.64 Bn in 2025, rising to about $8.65 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Cancer Immunotherapy market in France growing?
Placeholder estimate: about 10.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Cancer Immunotherapy market report cover?
The report splits the market by type (Checkpoint Inhibitors, Cell Therapies, Cancer Vaccines, Cytokines), indication (Lung Cancer, Melanoma, Blood Cancers, Others) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Cancer Immunotherapy market?
Key players include Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca and Regeneron Pharmaceuticals.
What is driving the Cancer Immunotherapy market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the cancer Immunotherapy market. Faster approvals and new combinations are improving survival.
Who regulates Cancer Immunotherapy in France?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency. Source: ANSM, French medicines agency. Checked 14 Nov 2026.
How is healthcare paid for in France?
National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover. Source: Assurance Maladie (ameli.fr). Checked 14 Nov 2026.
How many clinical trials on Cancer Immunotherapy are running in France?
184 studies are recruiting, active or about to start in France, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.
How much research is published on Cancer Immunotherapy?
PubMed lists 16,264 papers on Cancer Immunotherapy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in France

See all

Related on oncology

See the topic